Navigation Links
B. Braun Offers Wound Patients a New 'Over-the-Counter' Wound Management Gel - Prontosan®

BETHLEHEM, Pa., Jan. 10, 2011 /PRNewswire/ -- In its continued effort to advance best practices in wound care management, B. Braun Medical Inc. (B. Braun) announced today that Prontosan® Wound Management Gel with PHMB (Polyhexanide), a product used in the healthcare setting for cleaning wounds as well as moistening and lubricating absorbent wound dressings, is now available for over-the-counter (OTC) use. The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Prontosan® Wound Management Gel for OTC use in November 2010.


"Effective wound care management no longer needs to be limited to within healthcare facility walls," said Mike Kelly, Director of Marketing, Infection Control Products for B. Braun Medical Inc. "The 510(k) clearance for over-the-counter use of Prontosan® Wound Management Gel advances B. Braun's commitment to infection prevention, helping to provide solutions that positively impact patients' care – in a physician's office, acute care setting or in a patient's home."

Prontosan® aids in the thorough removal of dirt and debris from chronic wounds, skin ulcers and abrasions, even when surfaces are difficult to access (i.e. skin folds, fissures and wound pockets), and can be used to cleanse and soften encrusted wound coatings.

The ready-to-use gel contains PHMB and Betaine, the surfactant for the cleansing and moistening of wounds. PHMB has quickly gained popularity among healthcare professionals as a wound irrigation cleanser. Its non-toxic and biocompatible formula offers excellent skin tolerance.

"Since Prontosan® Wound Management Gel no longer requires a prescription, physicians can rest assured that patients will have access to the easy-to-use wound care product after they are discharged," said David Armstrong, DPM, MD, PhD, Professor of Surgery, University of Arizona.

With a shelf life of 28 days after opening, Prontosan® Wound Management Gel promotes the release of fibrin coatings and residue from wound coatings, and inhibits microorganisms from developing in the product. The gel's PVC-free and DEHP-free product containers also make it environmentally friendly. Prontosan® was originally made available for physician-only use by B. Braun in the fall of 2009.

For more information about Prontosan® Wound Gel with PHMB (Polyhexanide), please call: 1-800-227-2862. To order Prontosan® online, visit  

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at or visit B. Braun at

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Voluntarily Recalls Seven Lots of Heparin Manufactured in 2008 Due to Supplier-Initiated Recall of Heparin Active Pharmaceutical Ingredient (API)
2. B. Braun Wins Third Consecutive Safety IV Catheters Contract Award from Premier, Inc.
3. FDA-Approved Cefepime Now Available for Use in B. Brauns DUPLEX® System
4. B. Braun Customers Gain Premier Access to Zynx Health Device Networks Evidence-based, Customizable Drug Library Program
5. B. Braun Large Volume Heparin Infusion Solutions Now Available
6. New Technology Center Increases B. Brauns Infusion Pump Capacity
7. Health Robotics Re-Acquires CytoCares European Rights from B. Braun Melsungen AG for Undisclosed Consideration
8. FDA Approves Cefepime for Use In B. Brauns DUPLEX(R) System
9. B. Braun Renal Therapies Division Announces Availability of Adimea
10. B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
11. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 ... global pharmaceutical company, and Rugen Therapeutics, a start-up ... treatments for unmet CNS disorders and funded by ... that they have entered into an exclusive collaboration ... therapies for Autism Spectrum Disorders (ASD) and Obsessive ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ ... "Company") (NYSE: MR ), a ... medical devices worldwide, today announced that ... general meeting of shareholders at the ... Grand Century, 193 Prince Edward West Road, ...
(Date:11/25/2015)... , November 25, 2015 /PRNewswire/ ... announced the addition of the  "Global ...  report to their offering.  ... the addition of the  "Global Drug ...  report to their offering.  --> ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many ... the doctor uses other traditional cutting tools, such as the scalpel and high-speed drill, ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... ... sizes, has launched their Black Friday sale a week early, offering 40% off ... to transform the intimate apparel industry through both mobile fit technology and the ...
(Date:11/24/2015)... ... 24, 2015 , ... The hospitals and health systems on ... orthopedic care. They have received recognition for excellence from various reputable organizations in ... Becker's Hospital Review selected hospitals for inclusion based on national rankings and awards ...
(Date:11/24/2015)... Berkeley, California (PRWEB) , ... November 24, 2015 ... ... Brillouin Energy's LENR HHT Bolier Reactor System. Brillouin is the developer of renewable ... on controlled low energy nuclear reactions (“LENR”), announced today that its WET™ and ...
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association of Poison ... poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, the Tuesday ... inspires people to collaborate in improving their local communities and help give back ...
Breaking Medicine News(10 mins):